Apigenin
Apigenin (Chamomile Extract) · also known as Chamomile extract, Apigenin, Apigenin
In in-vitro and mouse experiments, apigenin can inhibit CD38 and raise liver NAD+, but its target occupancy in humans is unclear. Its sedative effect may involve GABAergic pathways, though receptor-level evidence is inconsistent and a sedative effect in humans has not been established.
Clinical uses and human evidence
Anxiety and stress
Sleep quality
Mechanisms of action
GABA and glutamate balance (inhibitory and excitatory tone)
Animal studies suggest apigenin’s sedative effect may involve GABAergic pathways. However, a benzodiazepine-site antagonist blocked only part of the sedative effects and receptor-level results are inconsistent, so its specificity for that site cannot yet be determined. A sedative effect in humans has not been established, and this cannot be taken to mean that ataxia will not occur.
Inhibition of NF-κB / AP-1, the master switches of pro-inflammatory transcription
Animal studies support the idea that apigenin suppresses NF-κB-related SASP pro-inflammatory signaling. Its pathway effects in human tissue after oral dosing are unclear, and this mechanism currently rests mainly on cell and animal work.
CD38 ectonucleotidase inhibition (a brake on NAD+ consumption)
In enzyme assays, apigenin inhibited CD38 with an IC50 of about 10.3 μmol/L, and liver NAD+ rose in treated mice. However, this in-vitro inhibitory concentration is far above the plasma levels measured in human dietary studies, and whether 50–200 mg of pure apigenin can reach an effective free exposure in humans has not been confirmed.
References (2)
- Escande 2013 · Enzyme assay and mouse study: apigenin inhibited CD38 with an in-vitro IC50 of about 10.3 μmol/L, and liver NAD+ rose in treated mice
- 2006 · 11-person pharmacokinetic study: after eating apigenin-rich parsley, peak plasma concentration was about 0.127 μmol/L (a different form from pure apigenin)
Apoptosis-driven clearance of senescent cells (senolytic activity)
In cell and mouse studies, apigenin reduced the senescence-associated secretory phenotype (SASP) and lowered the output of pro-inflammatory cytokines. But suppressing the secretory phenotype is not the same as clearing senescent cells, and there is currently no reliable evidence that apigenin selectively clears senescent cells.
Safety and drug interactions
Additive sedation
Has a mild sedative effect. Each of these has some sedative or sleep-promoting effect. Taken together, they may cause daytime drowsiness and slower reactions. Do not drive or work at heights after taking them.